Phase 3 trials demonstrated that even doses two to three times higher than standard therapeutic levels caused manageable nausea and vomiting but not organ damage or mortality
#CagriSema #Cagrilintide #Semaglutide #GLP1 #Obesity #WeightLoss #Amylin #MetabolicHealth #Cardiometabolic #ClinicalTrials To view or add a comment, sign in OZEMPIC (SEMAGLUTIDE): REVOLUTIONIZING T2DM & OBESITY CARE: A must-know for every clinician and pharmacist on the frontline of metabolic care
Some possible healthcare-related risks of obesity include: Type 2 diabetes Heart disease and heart attacks Arthritis Gallbladder and fatty liver disease High cholesterol and high blood pressure Circulation problems and increase risks for stroke Infertility Osteoarthritis, in particular, the knees Sleep apnea and other breathing problems Certain kinds of cancer endometrial, breast, and colon Strain on bones, joints, and muscles due to increased weight Mobility issues Metabolic syndrome Emotional issues kidney disease and many others Semaglutide May Also Decrease Cardiometabolic Risks in Obese Patients Some medical experts predict that if obesity cases continue to rise, research has shown over the past three decades in the U.S., up to 50% of the population may be diagnosed with obesity by the year 2030
Magistrelli L, Comi C
It isnt unique to this drug
Who should avoid self-directed recovery peptides
